Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: A randomised trial

British Journal of Cancer

Volumn 111, Issue 11, 2014, Pages 2187-2196

  Haguenoer, K ^a,b   Sengchanh, S ^b   Gaudy Graffin, C ^b,c,d   Boyard, J ^b   Fontenay, R ^b   Marret, H ^b,c   Goudeau, A ^b,c,d   Pigneaux De Laroche, N ^e   Rusch, E ^b,c   Giraudeau, B ^a,c,d  

^a PARIS DESCARTES UNIVERSITY   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d INSERM   (France)

^e Regional Institute for Health   (France)

Author keywords

cervical cancer; mass screening; non attendees; participation; self sampling

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; CERVICOVAGINAL SELF-SAMPLING DEVICE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HOME CARE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MAJOR CLINICAL STUDY; MIDDLE AGED; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL; SAMPLING; UTERINE CERVIX CANCER; VAGINA SMEAR; VAGINAL SELF SAMPLING; VIROLOGY; WART VIRUS; COST BENEFIT ANALYSIS; DIAGNOSTIC KIT; EARLY DIAGNOSIS; ECONOMICS; FOLLOW UP; PATIENT PARTICIPATION; PROCEDURES; UTERINE CERVIX TUMOR;

DIAGNOSTIC KIT;

ADULT; AGED; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PATIENT PARTICIPATION; REAGENT KITS, DIAGNOSTIC; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84927174089     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.510     Document Type: Article

References (42)

1. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von Karsa L (2010) European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition-summary document. Ann Oncol 21: 448-458.
2. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A (2009) Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 45: 2640-2648.
3. ArbynM, RoncoG, Anttila A, CJLMMeijer, PoljakM,Ogilvie G, KoliopoulosG, Naucler P, Sankaranarayanan R, Peto J (2012) Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30(Suppl 5): F88-F99.
4. Arbyn M, Verdoodt F, Snijders PJF, Verhoef VMJ, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao F-H, Hillemanns P, Anttila A (2014) Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 15: 172-183.
5. Van Baars R, Bosgraaf RP, ter Harmsel BWA, Melchers WJG, Quint WGV, Bekkers RLM (2012) Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, providing reliable human papillomavirus detection combined with comfort for women. J Clin Microbiol 50: 3937-3943.
6. Bais AG, van Kemenade FJ, Berkhof J, Verheijen RHM, Snijders PJF, Voorhorst F, Babovic M, van Ballegooijen M, Helmerhorst TJM, Meijer CJLM (2007) Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 120: 1505-1510.
7. Belinson JL, Hu S, Niyazi M, Pretorius RG, Wang H, Wen C, Smith JS, Li J, Taddeo FJ, Burchette RJ, Qiao Y-L (2010) Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: Implications for vaginal selfcollection. Int J Cancer 127: 1151-1157.
8. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. CONSORT Group (2008) Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med 148: 295-309.
9. Broberg G, Gyrd-Hansen D, Miao Jonasson J, Ryd M-L, Holtenman M, Milsom I, Strander B (2014) Increasing participation in cervical cancer screening: Offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer 134: 2223-2230.
10. Cerigo H, Coutlee F, Franco EL, Brassard P (2012) Dry self-sampling versus provider-sampling of cervicovaginal specimens for human papillomavirus detection in the Inuit population of Nunavik, Quebec. J Med Screen 19: 42-48.
11. Darlin L, Borgfeldt C, Forslund O, Henic E, Dillner J, Kannisto P (2013a) Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity. J Clin Virol 56: 52-56.
12. Darlin L, Borgfeldt C, Forslund O, Henic E, Hortlund M, Dillner J, Kannisto P (2013b) Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening. J Clin Virol 58: 155-160.
13. Duport N, Salines E, Gremy I (2014) [First results of the experimental evaluation of the French organized cervical cancer screening program, 2010-2012]. Bull Epidemiol Hebd 13-14-15: 228-234.
14. Eperon I, Vassilakos P, Navarria I, Menoud P-A, Gauthier A, Pache J-C, Boulvain M, Untiet S, Petignat P (2013) Randomized comparison of vaginal self-sampling by standard vs. dry swabs for human papillomavirus testing. BMC Cancer 13: 353.
15. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr. accessed 29 January 2014.
16. Fontaine V, Mascaux C, Weyn C, Bernis A, Celio N, Lefevre P, Kaufman L, Garbar C (2007) Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens. J Clin Microbiol 45: 928-934.
17. French National Authority for Health (2002) [Follow-up Guidelines for a Patient With an Abnormal Pap Smear Test Result. 2002 Updated Data].
18. French National Authority for Health (2012) Choices in Methods for Economic Evaluation (Department of Economics and Public Health Assessment).
19. Gakidou E, Nordhagen S, Obermeyer Z (2008) Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 5: e132.
20. Giorgi Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, Di Pierro C, Grazzini G, Angeloni C, Capparucci P, Pellegrini A, Schiboni ML, Sperati A, Confortini M, Bellanova C, D'Addetta A, Mania E, Visioli CB, Sereno E, Carozzi F (2011) The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br J Cancer 104: 248-254.
21. Gok M, Heideman DAM, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JWM, Voorhorst F, Belien JAM, Babovic M, Snijders PJF, Meijer CJLM (2010) HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 340: c1040.
22. Gok M, van Kemenade FJ, Heideman DAM, Berkhof J, Rozendaal L, Spruyt JWM, Belien JAM, Babovic M, Snijders PJF, Meijer CJLM (2012) Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer 130: 1128-1135.
23. Goldie SJ, Kim JJ, Wright TC (2004) Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 103: 619-631.
24. Gravitt PE, Rositch AF (2014) HPV self-testing and cervical cancer screening coverage. Lancet Oncol 15: 128-129.
25. Haguenoer K, Giraudeau B, Gaudy-Graffin C, de Pinieux I, Dubois F, Trignol-Viguier N, Viguier J, Marret H, Goudeau A (2014) Accuracy of dry vaginal self-sampling for detecting high-risk human papillomavirus infection in cervical cancer screening: a cross-sectional study. Gynecol Oncol 134: 302-308.
26. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, Altman DG, Barbour V, Macdonald H, Johnston M, Lamb SE, Dixon-Woods M, McCulloch P, Wyatt JC, Chan A-W, Michie S (2014) Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 348: g1687.
27. IARC (2005) IARC handbooks of cancer prevention: cervix cancer screening.
28. Laiairai E, Day NE, Hakama M (1987) Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1: 1247-1249.
29. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJF, Meijer CJLM (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
30. Racey CS, Withrow DR, Gesink D (2013) Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and metaanalysis. Can J Public Health 104: e159-e166.
31. Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn L-J, Porras C, Silva S, Gonzalez P, Bratti MC, Rodriguez AC, Castle P (2007) Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol 45: 1447-1454.
32. Sancho-Garnier H, Tamalet C, Halfon P, Leandri FX, Le Retraite L, Djoufelkit K, Heid P, Davies P, Piana L (2013) HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in France. Int J Cancer 133: 2681-2687.
33. Schmeink CE, Bekkers RLM, LFAG Massuger, Melchers WJG (2011) The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening. Rev Med Virol 21: 139-153.
34. Snijders PJF, Verhoef VMJ, Arbyn M, Ogilvie G, Minozzi S, Banzi R, van Kemenade FJ, Heideman DAM, Meijer CJLM (2013) High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 132: 2223-2236.
35. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright Jr T, Young N (2002) The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287: 2114-2119.
36. Szarewski A, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Edwards R, Lyons D, Walker J, Christison J, Frater A, Waller J (2011) HPV self-sampling as an alternative strategy in non-attenders for cervical screening-a randomised controlled trial. Br J Cancer 104: 915-920.
37. Tamalet C, Richet H, Carcopino X, Henry M, Leretraite L, Heid P, Leandri F-X, Sancho-Garnier H, Piana L (2010) Testing for human papillomavirus and measurement of viral load of HPV 16 and 18 in self-collected vaginal swabs of women who do not undergo cervical cytological screening in Southern France. J Med Virol 82: 1431-1437.
38. Virtanen A, Anttila A, Luostarinen T, Nieminen P (2011a) Self-sampling versus reminder letter: effects on cervical cancer screening attendance and coverage in Finland. Int J Cancer 128: 2681-2687.
39. Virtanen A, Nieminen P, Luostarinen T, Anttila A (2011b) Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 20: 1960-1969.
40. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
41. Wikstrom I, Lindell M, Sanner K, Wilander E (2011) Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. Br J Cancer 105: 337-339.
42. Zhang S-K, Ci P-W, Velicer C, Kang L-N, Liu B, Cui J-F, Chen F, Zhang X, Chang IJ, Roberts CC, Smith JS, Chen W, Qiao Y-L (2014) Comparison of HPV genotypes and viral load between different sites of genital tract: the significance for cervical cancer screening. Cancer Epidemiol 38: 168-173.